Skip to content

Prediction of cancer-associated venous thromboembolism

Validation and comparison of risk prediction scores for venous thromboembolism in ambulatory cancer patients.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON23071
Enrollment
2000
Registered
2019-09-09
Start date
2019-06-26
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer-associated venous thromboembolism

Interventions

None listed

Sponsors

Amsterdam UMC
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: - Adult patients (age >18 years) - Ambulatory setting - Histologically or cytologically confirmed cancer - Chemotherapy indicated within 3 months

Exclusion criteria

Exclusion criteria: - Desmoid tumors - Pre-stages of cancer

Design outcomes

Primary

MeasureTime frame
-Venous thromboembolism in the 6 months following cancer diagnosis

Secondary

MeasureTime frame
- Venous thromboembolism in 12 months and longer follow-up periods after cancer diagnosis. - Venous thromboembolism in the 6 months, 12 months and longer follow-up periods after reactivation of cancer. - Arterial thromboembolism in 6 months, 12 months and longer follow-up periods after primary cancer diagnosis or reactivation of cancer. - Mortality in 6 months, 12 months, and longer follow-up periods after primary cancer diagnosis.

Contacts

Public ContactFrits Mulder

Academic Medical Center

f.i.mulder@amsterdamumc.nl+31 20 566 1925

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)